pharmaphorum2d
GSK gets ready for its next big vaccine launch
GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya. The shot protects ...
pharmaphorum4d
GSK files shingles vaccine in EU
GlaxoSmithKline has filed its shingles vaccine in Europe, as it seeks to boost sales with a new wave of drugs. The EU filing of Shingrix follows a US filing last month for the drug, which analysts ...
Benzinga.com1mon
FDA Approves GSK's 5-in-1 Meningococcal Vaccine For Adolescents Ahead Of CDC Advisory Committee Vote Meeting Next Week
The FDA approved GSK's Penmenvy vaccine for ages 10-25, targeting five major meningococcal serogroups: A, B, C, W, and Y. Phase 3 trials with 4,800 participants showed the vaccine has a safety ...
Yahoo Finance1mon
PENMENVY, GSK’s 5-in-1 Meningococcal Vaccine, Approved by US FDA to Help Protect Against MenABCWY
Tony Wood, Chief Scientific Officer, GSK, said: "We are excited about the ... Pentavalent MenABCWY vaccines could help address the disease by providing protection against the five vaccine ...
Healio1mon
FDA approves GSK’s pentavalent meningococcal vaccine
CDC vaccine advisors are set to discuss recommendations for the vaccine on Feb. 26. The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 ...